ohashi koji

Epidemiological and experimental studies have shown that low methylmercury (MeHg) exposure causes cytotoxic effects. As to such cytotoxic effects, we have supposed that not only MeHg itself but also MeHg interacting with living environmental factors may cause cytotoxic effects. MeHg exposure is known to induce oxidative stress and cell death via ferroptosis in hepatocytes. In this study, we examined whether MeHg exposure followed by palmitic acid (PA) exposure at low non-toxic concentrations cause oxidative stress and cell death in HepG2 cells. In HepG2 cells combinedly exposed to MeHg and PA at low non-toxic concentrations, cell viability and glutathione peroxidase 4 expression levels were significantly decreased, while reactive oxygen species level was significantly increased. Ferrostatin-1 pretreatment suppressed oxidative stress and cell death found in the HepG2 cells. These results indicate that combined exposure to MeHg and PA at low non-toxic concentrations induces oxidative stress associated cell death in HepG2 cells.

BACKGROUND: Cardiovascular disease (CVD) remains a leading cause of death in Japan. Although several CVD risk scores tailored for Japanese individuals have been developed, no tools are available to estimate these scores at the population level. We developed the "Jcvrisk" R package, which integrates four major Japanese CVD risk models recommended by the clinical guideline. As a showcase, we applied the Jcvrisk package to longitudinal population-based study to evaluate trends in estimated different risk scores. METHODS: We used longitudinal data from the Yakumo Study, an annual health checkup for residents in Yakumo, Hokkaido. This package includes four risk models with 14 risk scores from representative cardiovascular cohort studies, including three EPOCH scores, one Hisayama score, two Suita scores, and eight JALS scores. For temporal comparisons of CVD risk scores, we summarized scores from 2000 to 2020 every five years. RESULTS: The mean age of participants throughout all study years was around 60 years old. Most risk factors did not change remarkably over the 20 years, with only a decrease in smoking prevalence and an increase in high density lipoprotein cholesterol (HDL-C). However, all CVD risk scores consistently indicated an upward trend in 10-year CVD risk. CONCLUSIONS: Jcvrisk package includes functions to calculate CVD risk scores for Japanese adults. The package serves as a valuable tool for researchers and policymakers aiming to assess and monitor cardiovascular risk at both individual and population levels in Japan.

BACKGROUND: Current evidence suggests an increased risk for cancer mortality in those with low aryl hydrocarbon receptor repressor (AHRR) DNA methylation (DNAm) levels. Therefore, AHRR DNAm could identify a more "fragile" group at risk for cancer mortality than questionnaire-based evaluations. Given this, the aim was to identify "fragile" groups at risk of cancer mortality by integrating questionnaire-based smoking indices and leukocyte AHRR DNAm levels in the Japanese population. METHODS: The target population was 795 participants without a clinical history who underwent a health checkup in 1990. They were followed for up to 30 years for mortality. The AHRR DNAm levels in leukocytes were measured by the pyrosequencing method. HRs for cancer mortality were calculated using a Cox proportional hazards model. RESULTS: Significantly higher HRs for all-cancer mortality were observed in low AHRR DNAm groups regardless of smoking intensity [pack-years <20: 3.69 (1.46-9.37); pack-years ≥20: 2.13 (1.11-4.09)]. Compared with current smokers, significantly lower HRs for all-cancer mortality were observed in the group with high AHRR DNAm regardless of years since quitting [YSQ ≤10: 0.13 (0.02-0.96); YSQ >10: 0.28 (0.08-0.98)]. Even for YSQ greater than 10, there was no significant mortality risk reduction in the low AHRR DNAm group. CONCLUSIONS: The population with low AHRR DNAm levels had a higher risk of cancer mortality even with low smoking exposure. Furthermore, no significant risk reduction was observed in former smokers with low AHRR DNAm levels. IMPACT: AHRR DNAm levels in leukocytes may help identify groups at risk for cancer mortality overlooked by questionnaire-based smoking indices.